Immunwork

T-E Pharma's subsidiary, Immunwork, Inc., announced that its proprietary ultralong-acting GLP-1 receptor agonist (GLP-1 RA), TE-8105, has received approval from an Australian Human Research Ethics Committee (HREC), officially enabling the initiation of it

T-E Pharma's subsidiary, Immunwork, Inc., recently announced that the latest research findings on its next-generation long-acting octreotide analog TE-8214 have been officially published in the internationally recognized journal Frontiers in Endocrinology

International technology and health media Tech Times recently featured Immunwork's long-acting GLP-1 receptor agonist TE-8105, highlighting its First-in-Human clinical results and novel fatty acid bundle molecular design. According to the report, TE-8105

First-in-Human Clinical Results Published in The Journal of Clinical Pharmacology and Presented at WCP2026 T-E Pharma's subsidiary, Immunwork, Inc., announced that the First-in-Human (FIH) Phase 1/2a clinical study results of TE-8105, a long-acting GLP-1

We're excited to announce that Dr. Art Hsing-Mao Chu, CEO of T-E PHARMA, will be presenting at the Investment Summit Session of BIO Asia-Taiwan 2026 conference. Time: 16:15-17:20 Roadshow, Wednesday, July 15, 2026 Venue: Room 701AB, 7F, TaiNEX2 Dr. Chu wi

T-E Pharma is honored to be invited by the Journal of the Chinese Chemical Society (JCCS) to publish a review article introducing our core technology platform "Multi-Arm Linkers", highlighting its innovative design and broad applications in novel drug dev

T-E Pharma has officially launched its pre-initial public offering (pre-IPO) fundraising program. The proceeds will be used to accelerate the development of its novel therapeutic pipeline, expand its global strategic presence, and strengthen its capital s

Great news! The long-acting GLP-1 receptor agonist TE-8105 has achieved an innovative breakthrough in formulation development, successfully creating a more convenient sublingual delivery form! We are thrilled to announce the publication of our paper, enti

We are honored to announce that Dr. Tse-Wen Chang, Chairman of T-E Pharma, and Dr. Hsin-Mao Chu, CEO of the T-E Pharma, have been invited to participate in BIOLOGICS WORLD TAIWAN 2026, to be held in Taiwan, where they will deliver keynote presentations. C

"The development of TE-6168, the novel thrombolytic fusion protein" was selected as a significant case of the Center for Drug Evaluation (CDE), Taiwan. The CDE case number is 115IDX02001.